2004 Fiscal Year Final Research Report Summary
Thyroid cancer study for establishment of prognostic marker and molecular targeting therapy using gene mutation analysis.
| Project/Area Number |
15590981
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Endocrinology
|
|---|
| Research Institution | Nagasaki University |
|---|
Principal Investigator |
NAMBA Hiroyuki Nagasaki University, Graduate School of Biomedical Science, Associate Professor, 大学院・医歯薬学総合研究科, 助教授 (80237635)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NAKASHIMA Masahiro Nagasaki University, Graduate School of Biomedical Science, Lecturer, 大学院・医歯薬学総合研究科, 講師 (50284683)
MAEDA Shigeto Nagasaki University, Hospital of Medicine and Dentistry, Research Associate, 医学部・薬学部附属病院, 助手 (40315247)
YAMASHITA Shunichi Nagasaki University, Graduate School of Biomedical Science, Professor, 大学院・医歯薬学総合研究科, 教授 (30200679)
|
|---|
| Project Period (FY) |
2003 – 2004
|
| Keywords | Thyroid Cancer / Oncogene / BRAF gene / Clinical Stage / Prognostic Marker / Aspiration Biopsy / Molecular Targeting Therapy |
|---|
| Research Abstract |
High prevalence of mutations in BRAF gene which mostly restricted in exon 15 codon 600 (BRAF^<V600E>) was found in thyroid papillary carcinomas. BRAF is one of the RAF kinase protein family proteins that were located downstream of RAS. BRAF is a serine/threonine kinase and operates as intracellar signal transfer factor to MEK1/2.
BRAF^<V600E> is detected in the different frequency between adult and childhood thyroid carcinomas. It is recognizes about 30 to 60 % of adult papillary thyroid carcinomas. Detailed histopathological analysis have revealed high frequency of BRAF^<V600E> mutation in classical papillary type and tall cell variant type, but low frequency in follicular variant type. These findings suggest that BRAF mutation is closely related with papillary transforming of thyroid epithelial cells in adulthood. Our study puts forward that pre-operative BRAF gene analysis to confirm the diagnosis through the use of specificity of BRAF mutation to adult papillary thyroid carcinoma. Furthermore, we have reported low frequency of BRAF mutation among childhood papillary thyroid carcinomas. We.also reported the good effects of taxsol and NF-kB inhibitor, DHMEQ to anaplastic thyroid cancer as a new molecular targeting therapeutic drugs.
|
